MX2023003255A - Polipeptidos efectores crispr-cas y metodos para su uso. - Google Patents

Polipeptidos efectores crispr-cas y metodos para su uso.

Info

Publication number
MX2023003255A
MX2023003255A MX2023003255A MX2023003255A MX2023003255A MX 2023003255 A MX2023003255 A MX 2023003255A MX 2023003255 A MX2023003255 A MX 2023003255A MX 2023003255 A MX2023003255 A MX 2023003255A MX 2023003255 A MX2023003255 A MX 2023003255A
Authority
MX
Mexico
Prior art keywords
present disclosure
cas effector
rna
crispr
disclosure provides
Prior art date
Application number
MX2023003255A
Other languages
English (en)
Inventor
Jennifer A Doudna
Jillian F Banfield
Basem Al-Shayeb
Patrick Pausch
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2023003255A publication Critical patent/MX2023003255A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente descripción proporciona proteínas efectoras CRISPR-Cas guiadas por ARN, ácidos nucleicos que las codifican y composiciones que las comprenden. La presente descripción proporciona complejos de ribonucleoproteína que comprende: una proteína efectora CRISPR-Cas guiada por ARN de la presente descripción; y un ARN guía. La presente descripción proporciona métodos para modificar un ácido nucleico objetivo mediante el uso de una proteína efectora CRISPR-Cas guiada por ARN de la presente descripción; y un ARN guía. La presente descripción proporciona métodos para modular la transcripción de un ácido nucleico objetivo.
MX2023003255A 2019-03-07 2021-09-02 Polipeptidos efectores crispr-cas y metodos para su uso. MX2023003255A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962815173P 2019-03-07 2019-03-07
US201962855739P 2019-05-31 2019-05-31
US201962907422P 2019-09-27 2019-09-27
US201962948470P 2019-12-16 2019-12-16

Publications (1)

Publication Number Publication Date
MX2023003255A true MX2023003255A (es) 2023-04-11

Family

ID=72338759

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021010559A MX2021010559A (es) 2019-03-07 2020-03-05 Polipéptidos efectores de crispr-cas y métodos de uso de estos.
MX2023003255A MX2023003255A (es) 2019-03-07 2021-09-02 Polipeptidos efectores crispr-cas y metodos para su uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021010559A MX2021010559A (es) 2019-03-07 2020-03-05 Polipéptidos efectores de crispr-cas y métodos de uso de estos.

Country Status (10)

Country Link
US (13) US11377646B2 (es)
EP (2) EP4219700A1 (es)
JP (2) JP7239725B2 (es)
CN (2) CN113811607A (es)
AU (2) AU2020231380A1 (es)
CA (1) CA3130789A1 (es)
DE (1) DE212020000516U1 (es)
GB (1) GB2595606B (es)
MX (2) MX2021010559A (es)
WO (1) WO2020181101A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3444347A1 (en) * 2017-08-18 2019-02-20 Universität Heidelberg Use of anti-crispr polypeptides for specific activation of cas nucleases
DE202019005567U1 (de) 2018-03-14 2021-02-16 Arbor Biotechnologies, Inc. Neue CRISPR-DNA-Targeting-Enzyme und -Systeme
US20210198664A1 (en) 2018-05-16 2021-07-01 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
EP3830301B1 (en) 2018-08-01 2024-05-22 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
CN113462672A (zh) * 2018-11-15 2021-10-01 中国农业大学 CRISPR-Cas12j酶和系统
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
WO2021216512A1 (en) * 2020-04-20 2021-10-28 The Regents Of The University Of California Crispr systems in plants
AU2021282578A1 (en) * 2020-06-03 2023-02-02 Mammoth Biosciences, Inc. Programmable nucleases and methods of use
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
EP4222167A1 (en) 2020-09-30 2023-08-09 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US20240067983A1 (en) * 2021-01-05 2024-02-29 Horizon Discovery Limited Guide RNA Designs and Complexes for Tracr-less Type V Cas Systems
EP4281555A1 (en) * 2021-01-25 2023-11-29 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
CN113373130B (zh) * 2021-05-31 2023-12-22 复旦大学 Cas12蛋白、含有Cas12蛋白的基因编辑系统及应用
EP4347818A2 (en) 2021-06-01 2024-04-10 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
WO2023004391A2 (en) 2021-07-21 2023-01-26 Montana State University Nucleic acid detection using type iii crispr complex
CN113862394B (zh) * 2021-08-12 2023-10-03 北京农业生物技术研究中心 一种番茄不孕病毒的rpa检测方法
WO2023028254A2 (en) * 2021-08-25 2023-03-02 Vanderbilt University Nucleotides comprising casphi modified for nuclear targeting
WO2023039373A2 (en) * 2021-09-08 2023-03-16 The Regents Of The University Of California Crispr-cas effector polypeptides and method of use thereof
CN113717962A (zh) * 2021-09-10 2021-11-30 武汉艾迪晶生物科技有限公司 用于水稻基因编辑的CasΦ-2蛋白及其表达盒子和表达载体
WO2023064923A2 (en) * 2021-10-15 2023-04-20 Mammoth Biosciences, Inc. Fusion effector proteins and uses thereof
CN114438055B (zh) * 2021-10-26 2022-08-26 山东舜丰生物科技有限公司 新型的crispr酶和系统以及应用
WO2023086938A2 (en) * 2021-11-12 2023-05-19 Arbor Biotechnologies, Inc. Type v nucleases
CN114480324B (zh) * 2022-01-13 2023-04-11 东北农业大学 一种可提高植物耐盐性的蛋白GsMYST1及其相关生物材料与应用
WO2023173105A2 (en) * 2022-03-10 2023-09-14 Saliogen Therapeutics, Inc. Tetracycline inducer/repressor system and simplified viral particle production
CN117460822A (zh) * 2022-04-25 2024-01-26 辉大基因治疗(新加坡)私人有限公司 新型CRISPR-Cas12i系统及其用途
WO2023220570A2 (en) * 2022-05-09 2023-11-16 Mammoth Biosciences, Inc. Engineered cas-phi proteins and uses thereof
WO2023250325A1 (en) * 2022-06-21 2023-12-28 The Regents Of The University Of California Compositions and methods for treating huntington's disease
WO2024041299A1 (zh) * 2022-08-25 2024-02-29 山东舜丰生物科技有限公司 突变的CRISPR-Cas蛋白及其应用
WO2024047587A1 (en) * 2022-08-31 2024-03-07 Regel Therapeutics, Inc. Cas-phi compositions and methods of use
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
CN117512071B (zh) * 2023-09-15 2024-06-04 湖北大学 一种耐高温TnpB蛋白及其在核酸检测中的应用

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5352605A (en) 1983-01-17 1994-10-04 Monsanto Company Chimeric genes for transforming plant cells using viral promoters
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5188958A (en) 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
US5750871A (en) 1986-05-29 1998-05-12 Calgene, Inc. Transformation and foreign gene expression in Brassica species
US5004863B2 (en) 1986-12-03 2000-10-17 Agracetus Genetic engineering of cotton plants and lines
US5359142A (en) 1987-01-13 1994-10-25 Monsanto Company Method for enhanced expression of a protein
US5322938A (en) 1987-01-13 1994-06-21 Monsanto Company DNA sequence for enhancing the efficiency of transcription
US5416011A (en) 1988-07-22 1995-05-16 Monsanto Company Method for soybean transformation and regeneration
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US6051753A (en) 1989-09-07 2000-04-18 Calgene, Inc. Figwort mosaic virus promoter and uses
EP0426641B1 (en) 1989-10-31 2000-09-13 Monsanto Company Promoter for transgenic plants
US5641876A (en) 1990-01-05 1997-06-24 Cornell Research Foundation, Inc. Rice actin gene and promoter
HU220773B1 (hu) 1990-01-22 2002-05-28 Dekalb Genetics Corporation Eljárás termő transzgenikus kukoricanövények előállítására
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5837848A (en) 1990-03-16 1998-11-17 Zeneca Limited Root-specific promoter
US5451513A (en) 1990-05-01 1995-09-19 The State University of New Jersey Rutgers Method for stably transforming plastids of multicellular plants
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994000977A1 (en) 1992-07-07 1994-01-20 Japan Tobacco Inc. Method of transforming monocotyledon
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
US5576198A (en) 1993-12-14 1996-11-19 Calgene, Inc. Controlled expression of transgenic constructs in plant plastids
US5545818A (en) 1994-03-11 1996-08-13 Calgene Inc. Expression of Bacillus thuringiensis cry proteins in plant plastids
US5545817A (en) 1994-03-11 1996-08-13 Calgene, Inc. Enhanced expression in a plant plastid
US5631152A (en) 1994-10-26 1997-05-20 Monsanto Company Rapid and efficient regeneration of transgenic plants
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
US5850019A (en) 1996-08-06 1998-12-15 University Of Kentucky Research Foundation Promoter (FLt) for the full-length transcript of peanut chlorotic streak caulimovirus (PCLSV) and expression of chimeric genes in plants
WO1998010080A1 (en) 1996-09-05 1998-03-12 Unilever N.V. Salt-inducible promoter derivable from a lactic acid bacterium, and its use in a lactic acid bacterium for production of a desired protein
HUP0000922A3 (en) 1997-01-20 2002-03-28 Plant Genetic Systems Nv Pathogen-induced plant promoters
US5922564A (en) 1997-02-24 1999-07-13 Performance Plants, Inc. Phosphate-deficiency inducible promoter
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US7022896B1 (en) 1997-04-04 2006-04-04 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
JP3880795B2 (ja) 1997-10-23 2007-02-14 ジェロン・コーポレーション フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法
AU762993C (en) 1998-02-26 2004-06-10 Pioneer Hi-Bred International, Inc. Constitutive maize promoters
CA2315549A1 (en) 1998-02-26 1999-09-02 Pioneer Hi-Bred International, Inc. Family of maize pr-1 genes and promoters
US6635806B1 (en) 1998-05-14 2003-10-21 Dekalb Genetics Corporation Methods and compositions for expression of transgenes in plants
US6307123B1 (en) 1998-05-18 2001-10-23 Dekalb Genetics Corporation Methods and compositions for transgene identification
JP2000083680A (ja) 1998-07-16 2000-03-28 Nippon Paper Industries Co Ltd 光誘導型プロモ―タ―の制御下に置かれた不定芽再分化遺伝子を選抜マ―カ―遺伝子とする植物への遺伝子導入方法及びこれに用いる植物への遺伝子導入用ベクタ―
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
EP1141346A2 (en) 1999-01-14 2001-10-10 Monsanto Co. Soybean transformation method
AU4657500A (en) 1999-04-21 2000-11-02 Pangene Corporation Locked nucleic acid hybrids and methods of use
US6194636B1 (en) 1999-05-14 2001-02-27 Dekalb Genetics Corp. Maize RS324 promoter and methods for use thereof
US6232526B1 (en) 1999-05-14 2001-05-15 Dekalb Genetics Corp. Maize A3 promoter and methods for use thereof
US6207879B1 (en) 1999-05-14 2001-03-27 Dekalb Genetics Corporation Maize RS81 promoter and methods for use thereof
US6429357B1 (en) 1999-05-14 2002-08-06 Dekalb Genetics Corp. Rice actin 2 promoter and intron and methods for use thereof
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
EP1230398B1 (de) 1999-11-16 2004-06-30 Atto-tec GmbH Farbstoffmarkiertes oligonukleotid zum markieren eines nukleinsäuremoleküls
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US6727356B1 (en) 1999-12-08 2004-04-27 Epoch Pharmaceuticals, Inc. Fluorescent quenching detection reagents and methods
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
EP1334109B1 (en) 2000-10-04 2006-05-10 Santaris Pharma A/S Improved synthesis of purine locked nucleic acid analogues
ATE437647T1 (de) 2001-02-16 2009-08-15 Cellgate Inc Transporter mit beabstandeten arginin-teilchen
US7053195B1 (en) 2001-06-12 2006-05-30 Syngenta Participatious Ag Locked nucleic acid containing heteropolymers and related methods
US8030000B2 (en) 2002-02-21 2011-10-04 Alere San Diego, Inc. Recombinase polymerase amplification
US6818420B2 (en) 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
DE10259374A1 (de) 2002-12-18 2004-07-08 Atto-Tec Gmbh Carboxamid-substituierte Farbstoffe für analytische Anwendungen
AU2004208031B2 (en) 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
DE10329860A1 (de) 2003-07-02 2005-01-20 Atto-Tec Gmbh Sulfonamidderivate polycyclischer Farbstoffe für analytische Anwendungen
US8586718B2 (en) 2004-09-14 2013-11-19 Applied Biosystems, Llc Multi-chromophoric quencher constructs for use in high sensitivity energy transfer probes
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof
WO2008106803A1 (en) 2007-03-07 2008-09-12 Nventa Biopharmaceuticals Corporation Double-stranded locked nucleic acid compositions
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
EP2268608A4 (en) 2008-04-01 2012-01-11 Biosearch Technologies Inc DARK NUCLEIC ACID STABILIZED FLUOROPHORE DEACTIVATOR PROBES
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US20110111403A1 (en) 2009-10-30 2011-05-12 Life Technologies Corporation Multi-primer assay for mycoplasma detection
WO2012027675A2 (en) 2010-08-26 2012-03-01 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
DE102010042634A1 (de) 2010-10-19 2012-04-19 Atto-Tec Gmbh Neue Amin-substituierte tricyclische Fluoreszenzfarbstoffe
US9580714B2 (en) 2010-11-24 2017-02-28 The University Of Western Australia Peptides for the specific binding of RNA targets
US10876160B2 (en) 2011-10-31 2020-12-29 Eiken Kagaku Kabushiki Kaisha Method for detecting target nucleic acid
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US20150218227A1 (en) 2012-04-16 2015-08-06 The University Of Westren Australia Peptides for the binding of nucleotide targets
DK3401400T3 (da) 2012-05-25 2019-06-03 Univ California Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering
JP6620018B2 (ja) 2012-12-06 2019-12-11 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ Ｃｒｉｓｐｒに基づくゲノム修飾および制御
MX2015007550A (es) 2012-12-12 2017-02-02 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
PT2898075E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
PT2896697E (pt) 2012-12-12 2015-12-31 Massachusetts Inst Technology Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
RU2678001C2 (ru) 2012-12-13 2019-01-22 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы обнаружения днк для сайт-специфической нуклеазной активности
EP3553174A1 (en) 2012-12-17 2019-10-16 President and Fellows of Harvard College Rna-guided human genome engineering
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
CA2901676C (en) 2013-02-25 2023-08-22 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
EP2971167B1 (en) 2013-03-14 2019-07-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CA2906747A1 (en) 2013-03-15 2014-09-18 Regents Of The University Of Minnesota Engineering plant genomes using crispr/cas systems
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
CA2907198C (en) 2013-03-15 2019-12-10 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US20140364333A1 (en) 2013-03-15 2014-12-11 President And Fellows Of Harvard College Methods for Live Imaging of Cells
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
CA2908512C (en) 2013-04-05 2023-10-24 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
CN111500630A (zh) 2013-04-16 2020-08-07 瑞泽恩制药公司 大鼠基因组的靶向修饰
US10604771B2 (en) 2013-05-10 2020-03-31 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2014190181A1 (en) 2013-05-22 2014-11-27 Northwestern University Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
US9873907B2 (en) 2013-05-29 2018-01-23 Agilent Technologies, Inc. Method for fragmenting genomic DNA using CAS9
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
DE102013215045B4 (de) 2013-07-31 2023-05-04 Siemens Healthcare Gmbh Dreheinheit mit einer Vorrichtung zur drahtlosen Datenübertragung zwischen zwei relativ zueinander bewegbaren Teilen sowie Verfahren zur drahtlosen Datenübertragung zwischen zwei relativ zueinander bewegbaren Teilen
US20160251410A1 (en) 2013-09-03 2016-09-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
CN107406838A (zh) * 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
EP3352795B1 (en) 2015-09-21 2020-08-12 The Regents of The University of California Compositions and methods for target nucleic acid modification
SG10202107602XA (en) * 2015-11-04 2021-08-30 Univ Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
EP3374494A4 (en) * 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. CRISPR COMPOSITIONS AND METHODS OF USE FOR GENE THERAPY
CA3009190A1 (en) * 2015-12-29 2017-07-06 Monsanto Technology Llc Novel crispr-associated transposases and uses thereof
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
AU2017335890B2 (en) 2016-09-30 2024-05-09 The Regents Of The University Of California RNA-guided nucleic acid modifying enzymes and methods of use thereof
KR20230169449A (ko) 2016-09-30 2023-12-15 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
BR112019015244A2 (pt) * 2017-03-24 2020-04-14 Curevac Ag ácidos nucleicos codificando proteínas associadas a crispr e usos dos mesmos
US20200115688A1 (en) * 2017-08-15 2020-04-16 The Regents Of The University Of California Compositions and methods for enhancing genome editing
EP3704239A4 (en) 2017-11-01 2021-08-18 The Regents of The University of California CASZ COMPOSITIONS AND METHOD OF USE
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
AU2019222568B2 (en) 2018-02-15 2021-10-14 Sigma-Aldrich Co. Llc Engineered Cas9 systems for eukaryotic genome modification
WO2019214604A1 (zh) * 2018-05-07 2019-11-14 中国农业大学 CRISPR/Cas效应蛋白及系统
US20210198664A1 (en) * 2018-05-16 2021-07-01 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
CN113462672A (zh) * 2018-11-15 2021-10-01 中国农业大学 CRISPR-Cas12j酶和系统
WO2020131862A1 (en) * 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
JP2022540153A (ja) * 2019-07-11 2022-09-14 アーバー バイオテクノロジーズ， インコーポレイテッド 新規ｃｒｉｓｐｒ ｄｎａターゲティング酵素及びシステム
US20220389438A1 (en) * 2019-10-22 2022-12-08 Inari Agriculture Technology, Inc. Genomic alteration of plant germline

Also Published As

Publication number Publication date
US11377646B2 (en) 2022-07-05
EP4219700A1 (en) 2023-08-02
US20210301271A1 (en) 2021-09-30
JP2023071855A (ja) 2023-05-23
US20210317428A1 (en) 2021-10-14
US20210317447A1 (en) 2021-10-14
GB2595606A (en) 2021-12-01
MX2021010559A (es) 2021-12-15
GB2595606B (en) 2022-09-21
US20230287375A1 (en) 2023-09-14
JP2022521771A (ja) 2022-04-12
US11685909B2 (en) 2023-06-27
CN113811607A (zh) 2021-12-17
US20240026321A1 (en) 2024-01-25
EP3935156A1 (en) 2022-01-12
GB202112233D0 (en) 2021-10-13
AU2023201675A1 (en) 2023-04-13
CN116732004A (zh) 2023-09-12
US20210254038A1 (en) 2021-08-19
US20210403888A1 (en) 2021-12-30
US11530398B2 (en) 2022-12-20
US20230323321A1 (en) 2023-10-12
DE212020000516U1 (de) 2022-01-17
AU2020231380A1 (en) 2021-09-23
US20210238567A1 (en) 2021-08-05
US11578313B2 (en) 2023-02-14
US20230332123A1 (en) 2023-10-19
CA3130789A1 (en) 2020-09-10
JP7239725B2 (ja) 2023-03-14
US20210324356A1 (en) 2021-10-21
EP3935156A4 (en) 2022-12-28
US20210324358A1 (en) 2021-10-21
US11739309B2 (en) 2023-08-29
US20220340889A1 (en) 2022-10-27
WO2020181101A1 (en) 2020-09-10
AU2023201675B2 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
MX2023003255A (es) Polipeptidos efectores crispr-cas y metodos para su uso.
MX2022007858A (es) Polipeptidos efectores crispr-cas y metodos de uso de estos.
MX2020004578A (es) Composiciones de casz y metodos de uso.
WO2020123887A3 (en) Novel crispr-cas systems for genome editing
PH12021551114A1 (en) Crispr-cas12j enzyme and system
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
MX2022005328A (es) Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
CR20220076A (es) Anticuerpos anti-cd96 y sus métodos de uso
WO2016130628A8 (en) Griffithsin mutants
MX2021005313A (es) Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico.
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
MX2023014077A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
WO2020061443A3 (en) Methods of making and using universal centralized influenza vaccine genes
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
WO2023102329A3 (en) Effector proteins and uses thereof
EP3795586A3 (en) Production of proteins in labyrinthulomycetes
WO2023039373A3 (en) Crispr-cas effector polypeptides and method of use thereof
MX2018003445A (es) Expresion de proteinas que contienen fc.